Rockefeller Capital Management’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.77M | Buy |
66,690
+29,789
| +81% | +$789K | ﹤0.01% | 1150 |
|
|
2025
Q1 | $891K | Buy |
36,901
+13,265
| +56% | +$320K | ﹤0.01% | 1305 |
|
|
2024
Q4 | $951K | Sell |
23,636
-10,387
| -31% | -$418K | ﹤0.01% | 1268 |
|
|
2024
Q3 | $2.15M | Buy |
34,023
+17,754
| +109% | +$1.12M | 0.01% | 965 |
|
|
2024
Q2 | $862K | Buy |
+16,269
| New | +$862K | ﹤0.01% | 1261 |
|
|
2023
Q3 | – | Sell |
-7,527
| Closed | -$122K | – | 1819 |
|
|
2023
Q2 | $122K | Buy |
+7,527
| New | +$122K | ﹤0.01% | 1752 |
|
|
2023
Q1 | – | Sell |
-1,461
| Closed | -$13K | – | 3830 |
|
|
2022
Q4 | $13K | Hold |
1,461
| – | – | ﹤0.01% | 2979 |
|
|
2022
Q3 | $3K | Sell |
1,461
-3,500
| -71% | -$7.19K | ﹤0.01% | 3519 |
|
|
2022
Q2 | $14K | Buy |
4,961
+2,437
| +97% | +$6.88K | ﹤0.01% | 2962 |
|
|
2022
Q1 | $7K | Hold |
2,524
| – | – | ﹤0.01% | 3236 |
|
|
2021
Q4 | $11K | Sell |
2,524
-700
| -22% | -$3.05K | ﹤0.01% | 2947 |
|
|
2021
Q3 | $20K | Buy |
3,224
+500
| +18% | +$3.1K | ﹤0.01% | 2600 |
|
|
2021
Q2 | $16K | Buy |
2,724
+2,000
| +276% | +$11.7K | ﹤0.01% | 2591 |
|
|
2021
Q1 | $4K | Buy |
724
+364
| +101% | +$2.01K | ﹤0.01% | 2984 |
|
|
2020
Q4 | $2K | Hold |
360
| – | – | ﹤0.01% | 2670 |
|
|
2020
Q3 | $2K | Buy |
360
+200
| +125% | +$1.11K | ﹤0.01% | 2428 |
|
|
2020
Q2 | $1K | Hold |
160
| – | – | ﹤0.01% | 2508 |
|
|
2020
Q1 | $1K | Buy |
160
+154
| +2,567% | +$963 | ﹤0.01% | 2316 |
|
|
2019
Q4 | $0 | Buy |
+6
| New | – | ﹤0.01% | 2221 |
|